ClinVar Miner

Submissions for variant NM_000546.6(TP53):c.431A>C (p.Gln144Pro)

dbSNP: rs786203071
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000166212 SCV000216991 pathogenic Hereditary cancer-predisposing syndrome 2021-01-12 criteria provided, single submitter clinical testing The p.Q144P pathogenic mutation (also known as c.431A>C), located in coding exon 4 of theTP53 gene, results from an A to C substitution at nucleotide position 431. The glutamine at codon 144 is replaced by proline, an amino acid with similar properties. This variant is located in the DNA binding domain of the TP53 protein, is reported to have loss of transactivation capacity in yeast based assays (IARC TP53 database; Kato S et al.Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8424-9). Studies conducted in human cell lines indicate this alteration is deficient at growth suppression and has a dominant negative effect (Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Labcorp Genetics (formerly Invitae), Labcorp RCV001850338 SCV002112810 uncertain significance Li-Fraumeni syndrome 2020-11-25 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this variant affects TP53 protein function (PMID: 12826609, 30224644, 29979965). This variant has not been reported in the literature in individuals with TP53-related conditions. ClinVar contains an entry for this variant (Variation ID: 186594). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamine with proline at codon 144 of the TP53 protein (p.Gln144Pro). The glutamine residue is highly conserved and there is a moderate physicochemical difference between glutamine and proline.
Genome-Nilou Lab RCV000166212 SCV002582084 uncertain significance Hereditary cancer-predisposing syndrome 2022-06-18 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV002288758 SCV002582647 uncertain significance Li-Fraumeni syndrome 1 2022-06-18 criteria provided, single submitter clinical testing
German Consortium for Hereditary Breast and Ovarian Cancer, University Hospital Cologne RCV000785331 SCV000923899 likely pathogenic Ovarian neoplasm 2018-12-01 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.